Endometriosis.
Krina T Zondervan, Christian M Becker, Stacey A Missmer
https://pubmed.ncbi.nlm.nih.gov/32212520Actively Recruiting
Led by Mỹ Đức Hospital · Updated on 2026-03-20
222
Participants Needed
1
Research Sites
37 weeks
Total Duration
Researchers are evaluating two different protocols for preparing the uterus lining (endometrium) before frozen embryo transfer (FET) in women with adenomyosis undergoing IVF/ICSI. The study aims to find out if combining GnRH agonist and letrozole with hormone therapy leads to higher live birth rates compared to hormone therapy alone. It also looks at the side effects of the combined protocol. Adenomyosis, a condition where uterine tissue invades muscle layers, can cause infertility and pregnancy complications, and optimal preparation methods are unclear. Participants are randomly assigned to one of two groups. The first group receives two doses of GnRH agonist injections and daily letrozole over two months before starting hormone therapy with oral estradiol and vaginal progesterone. The second group receives hormone therapy alone starting early in the menstrual cycle with oral estradiol followed by vaginal progesterone once the uterine lining is thick enough. Embryo thawing and transfer are timed with progesterone start. Hormonal support continues until the 12th week of pregnancy. Participants undergo screening and ultrasound to confirm adenomyosis and monitor uterine lining thickness. Various pregnancy outcomes, including live birth rate at 22 weeks, pregnancy tests, implantation, miscarriage, and birth weight, are tracked. Side effects from the treatments and pregnancy complications like gestational diabetes and hypertension are also monitored. The study includes careful follow-up until delivery and newborn health assessments. Total participation duration covers preparation, pregnancy monitoring, and birth outcomes.
CONDITIONS
Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Screening and enrollment visit conducted on days 2 to 4 of the menstrual cycle
Duration - Approximately 56 days
Participants in this group receive two injections of GnRH agonist and take daily Letrozole to prepare for endometrial treatment.
2 injections on days 2-4 of menstrual cycle and 28 days later; Letrozole taken daily during this period
Duration - At least 9 days before progesterone initiation
Participants start oral estradiol valerate to prepare the endometrium. Endometrial thickness is monitored, and vaginal progesterone is initiated once thickness reaches 7 mm or more.
Monitoring from day 10 of estradiol priming; 1 visit for thickness monitoring before progesterone start
Duration - Up to 12 weeks of gestation
Embryo transfer is scheduled based on progesterone initiation and embryo stage. Hormonal support continues until the 12th week of gestation.
Visits aligned with embryo transfer and hormonal support follow-up until week 12
Total: 1 location
1
My Duc Hospital
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 70000
Actively Recruiting
T
Tien K Le, MD
V
Vu NA Ho, MD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Krina T Zondervan, Christian M Becker, Stacey A Missmer
https://pubmed.ncbi.nlm.nih.gov/32212520Maria Szubert, Edward Koziróg, Olga Olszak...
https://pubmed.ncbi.nlm.nih.gov/33573117Maria Facadio Antero, Ayse Ayhan, James Segars...
https://pubmed.ncbi.nlm.nih.gov/33080632Sezcan Mumusoglu, Mehtap Polat, Irem Yarali Ozbek...
https://pubmed.ncbi.nlm.nih.gov/34305815Yiting Zhang, Xiao Fu, Shuli Gao...
https://pubmed.ncbi.nlm.nih.gov/37291605M J Harmsen, T Van den Bosch, R A de Leeuw...
https://pubmed.ncbi.nlm.nih.gov/34587658